Compare CDRO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRO | RZLT |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Luxembourg | United States |
| Employees | 325 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 326.4M |
| IPO Year | N/A | 2011 |
| Metric | CDRO | RZLT |
|---|---|---|
| Price | $8.35 | $2.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.00 | ★ $9.67 |
| AVG Volume (30 Days) | 13.2K | ★ 2.9M |
| Earning Date | 02-28-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | $305.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.18 | $1.07 |
| 52 Week High | $8.77 | $11.46 |
| Indicator | CDRO | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 48.31 |
| Support Level | $7.73 | $2.87 |
| Resistance Level | $8.69 | $3.65 |
| Average True Range (ATR) | 0.26 | 0.29 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 58.42 | 43.80 |
Codere Online Luxembourg SA is an international online casino gaming and online sports betting group focused on providing its customers with a safe and enjoyable online gaming experience. It currently operates in Spain, Mexico, Colombia, and Other countries. where it offers its users the ability to play online casino games and bet on sports events. Online casino offerings include the full portfolio of games typically available in land-based casinos, gaming halls and gambling establishments, such as slot machines, table games, and bingo. Online sports betting involves a user placing a wager on an event at some fixed odds determined by Codere Online. The company derives maximum revenue from Mexico.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.